Oct18

Morphic partners with investor AbbVie on integrin inhibitor development

The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.

Oct18

Novartis spends $2.1B to snap up targeted radiotherapy drug for prostate cancer

Endocyte entered its targeted radioligand therapy, Lu-PSMA-617, into a Phase III study in June following Phase II data showing more than 60 percent response rate.

Oct18

Exclusive: Remedy launches screening tool to uncover undiagnosed chronic illness

The San Francisco-based startup’s platform aids care coordinators to assess and identify both clinical and sociodemographic risk factors for chronic illnesses like diabetes, COPD, chronic kidney disease, depression and congestive heart failure.

Oct18

Voice tech is coming to healthcare

The Voice.Health Summit at the Connected Health Conference brought together a plethora of experts to discuss the pros of voice technology as well as why it’s still in its early days in the healthcare realm.

Oct17

An App Store for genomics

Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.

Oct17

An App Store for genomics

Helix, based near San Francisco, touts its API-based business model as a way to stand out among the plethora of personal genomics companies.

Oct17

How Oscar Health’s CEO charts its path forward in a changing payer landscape

Oscar Health CEO Mario Schlosser laid out what brought the company to where it is today and how it plans to lean into some of the larger shifts in the healthcare system during an onstage interview at Rock Health 2018 Summit in San Francisco.

Oct17

How Oscar Health’s CEO charts its path forward in a changing payer landscape

Oscar Health CEO Mario Schlosser laid out what brought the company to where it is today and how it plans to lean into some of the larger shifts in the healthcare system during an onstage interview at Rock Health 2018 Summit in San Francisco.